Manufacturing Chemist

Manufacturing Chemist stands out as one of the oldest and most reputable sources of information within the worldwide pharmaceutical manufacturing sector.

International, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#1414496

Malaysia

#57603

Health/Biotechnology and Pharmaceuticals

#15

Traffic sources

Monthly visitors

Articles

Top reasons to rent product inspection systems

1 month ago | manufacturingchemist.com | Kevin Robinson

By Kevin Robinson | Published: 11-Apr-2025 For manufacturers facing production challenges, renting product inspection systems can be a cost-effective and flexible solution You need to be a subscriber to read this article. Click here to find out more.
Trump's tariffs: an expert's take on pharmaceutical impact, where to go from here

1 month ago | manufacturingchemist.com | Annabel Kartal-Allen

The Trump Administration has decided to double down on its plan to slap tariffs on pharmaceutical imports, as revealed from live coverage from . This follows Donald J. Trump's decision to place baseline tariffs of 10% on almost every US import — though pharmaceuticals are currently exempted from this cost. “We’re going to put tariffs on the pharmaceutical companies, and they’re going to all want to come back,” he noted in a conversation with the press.
Quality and compliance: the foundation of trust

2 months ago | manufacturingchemist.com | Kevin Robinson

By Kevin Robinson | Published: 4-Apr-2025 As the CEO of Symbiosis, a contract manufacturing organisation (CMO) licenced to manufacture sterile medicinal products, Colin MacKay understands the profound responsibility involved in ensuring that the products they manufacture meet the highest quality standards and adhere to all relevant regulatory requirements You need to be a subscriber to read this article. Click here to find out more.
DCAT preview: the future of pharma manufacturing

Mar 10, 2025 | manufacturingchemist.com | Kevin Robinson

Thierry Van Nieuwenhove, CEO of Quotient Sciences recognises that sustainability and resilience are critical to the future of pharmaceutical development supply chains. As an industry, we must balance the need for innovation and speed with responsible environmental stewardship. Our ESG commitments at Quotient are deeply embedded in our mission to accelerate the development of new medicines while minimising our environmental impact.
Beginnings, endings and transitions: Janus and the business of pharmaceuticals

Feb 11, 2025 | manufacturingchemist.com | Kevin Robinson

By Kevin Robinson | Published: 10-Feb-2025 Dr Kevin Robinson recently caught up with pharmaceutical industry experts to review what they considered to be the sector’s key challenges and achievements in 2024 and what trends, technologies or regulatory shifts they anticipate will shape the industry in 2025 You need to be a subscriber to read this article. Click here to find out more.
Of data, devices and drug delivery

Jan 12, 2025 | manufacturingchemist.com | Kevin Robinson

By Kevin Robinson | Published: 13-Jan-2025 Ahead of Pharmapack Europe 2025 (22–23January, Paris, France), Dr Kevin Robinson (KSR) spoke with three pharma leaders about the big trends that will drive and influence the pharmaceutical sector in 2025 You need to be a subscriber to read this article. Click here to find out more.
Hybrid interferons: developing a novel drug class

Nov 27, 2024 | manufacturingchemist.com | Kevin Robinson

At ILC Therapeutics (ILCT), we are pioneering a novel drug class called hybrid interferons, Dawn Firmin, Chief Operating Officer, tells Dr Kevin Robinson. This is being driven by our platform technology, which has so far delivered two engineered cytokine candidates that are progressing towards the clinic. This article explores the journey so far, some of the specific challenges that have arisen and how we have faced them.
Why CGT manufacturers should automate the production process

Nov 27, 2024 | manufacturingchemist.com | Annabel Kartal-Allen

The impact of cell and gene therapies (CGTs) in the pharmaceutical market has grown significantly in recent years, with 10,000s of patients now benefitting from their efficacy. Many companies are developing their own pipelines in advanced disease indications such as cancer, autoimmune diseases and genetic disorders.
Why potency assays are a crucial consideration for CGT manufacturers

Oct 18, 2024 | manufacturingchemist.com | Annabel Kartal-Allen

As many begin to show proof-of-concept in a range of disease indications, cell and gene therapies (CGTs) have quickly become one of the most talked-about areas of development in the pharmaceutical industry. The US Food and Drug Administration (FDA) has now approved more than 30 CGTs and plenty more are currently making their way through clinical trials globally.
Navigating the world of cell and gene therapy development and commercialisation

Sep 27, 2024 | manufacturingchemist.com | Annabel Kartal-Allen

Initially discussing the latest trends in the biopharma industry, Adam notes that process analytical technology (PAT) has seen significant evolution in recent years and become an important component in terms of accelerating development timelines. PAT solutions enable the simple scaling of manufacturing processes to facilitate the production of biologics and cell and gene therapies (CGTs).